N
NeoTX Therapeutics
Specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy
About NeoTX Therapeutics
NeoTX Therapeutics, an Israeli biopharmaceutical company founded in 2015, is a clinical-stage entity focused on immuno-oncology. The company was co-founded by CEO Asher Nathan, a seasoned entrepreneur in the biotechnology sector with over 25 patents to his name. Nathan, who holds a BSc in chemistry and biology, has founded other biotech companies like IntelliGene and EvoRx, the latter in collaboration with Nobel Laureates Arthur and Roger Kornberg. His extensive background in biotechnology and business strategy drives NeoTX's mission to develop novel cancer therapies.
The company's core business revolves around its proprietary Tumor Targeted Superantigen (TTS) platform, sometimes referred to as Selective T cell Redirection (STR). This technology is founded on the principle that the immune system is more effective at fighting bacteria than cancer. The platform works by coating a tumor with a bacterial derivative, specifically a superantigen, which tricks the immune system into mounting a powerful antibacterial response against the cancer cells. This approach aims to convert a weak anti-tumor response into a durable one, potentially benefiting patients who do not respond to existing immunotherapy treatments. NeoTX's business model involves in-licensing, developing, and commercializing these targeted anticancer immunotherapies, often through partnerships and collaborations with other pharmaceutical companies and clinical trial organizations.
NeoTX's lead product candidate is Naptumomab estafenatox (NAP), a TTS molecule licensed from Active Biotech in 2016. NAP is a fusion protein that targets the 5T4 antigen, which is present on a wide variety of solid tumors, including non-small cell lung cancer (NSCLC), pancreatic, and renal cell cancers. The molecule is designed to bind to these cancer cells and then activate a patient's T-cells to attack the tumor. NeoTX is evaluating NAP in multiple clinical trials, both as a monotherapy and in combination with other cancer treatments like chemotherapy and checkpoint inhibitors. For instance, a Phase 1b trial is assessing NAP in combination with AstraZeneca's durvalumab, and a Phase 2 trial is studying its use with docetaxel for NSCLC. The company has raised over $100 million in funding to advance these clinical programs and to in-license new technologies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 36.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest May 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Feb 2020 | $45M | $180M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for NeoTX Therapeutics is 2K monthly website visits, up 81.8% over the last three months. NeoTX Therapeutics's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NeoTX Therapeutics in the Rehovot ecosystem
The NeoTX Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeoTX Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeoTX Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









